NASDAQ:AXDX Accelerate Diagnostics Q1 2024 Earnings Report $0.55 +0.01 (+1.69%) Closing price 04/25/2025 03:51 PM EasternExtended Trading$0.58 +0.02 (+4.15%) As of 04/25/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Accelerate Diagnostics EPS ResultsActual EPS-$0.88Consensus EPS -$0.72Beat/MissMissed by -$0.16One Year Ago EPSN/AAccelerate Diagnostics Revenue ResultsActual Revenue$2.92 millionExpected Revenue$3.00 millionBeat/MissMissed by -$80.00 thousandYoY Revenue GrowthN/AAccelerate Diagnostics Announcement DetailsQuarterQ1 2024Date5/8/2024TimeN/AConference Call DateWednesday, May 8, 2024Conference Call Time4:30PM ETUpcoming EarningsAccelerate Diagnostics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Thursday, May 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Accelerate Diagnostics Q1 2024 Earnings Call TranscriptProvided by QuartrMay 8, 2024 ShareLink copied to clipboard.There are 5 speakers on the call. Operator00:00:00day, and welcome to the Accelerate Diagnostics Incorporated Quarter 2024 Results Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions with our covering analysts. I would now like to turn the conference over to Ms. Laura Pearson of Accelerant Diagnostics. Operator00:00:17Please go ahead, ma'am. Speaker 100:00:21Before we begin, it is important to share that information presented during this call may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward looking statements include projections, statements about our future and those that are not historical facts. All forward looking statements are made during this conference call are subject to risks, uncertainties and other factors that could cause our results to differ materially. These are discussed in greater detail in our annual report on Form 10 ks for the year ended December 31, 2023, and other reports we file with the SEC. It is my pleasure to now introduce the company's President and CEO, Jack Phillips. Speaker 200:01:10Thank you, Laura. Good afternoon. Today, I would like to provide a detailed update on the WAVE program. Before I provide my update, I will pass it on to David Patience, our CFO, to summarize our financial results for the quarter. Speaker 300:01:25Thank you, Jack, and good afternoon, everyone. Net sales were approximately to approximately $2,800,000 for the same period in the prior year. This was driven by an increase in reoccurring consumable net sales. Gross margin was approximately 25% for the quarter, which compares to approximately 36% for the same period in the prior year. The overall decline in gross margin was driven by product mix. Speaker 300:01:56Selling, general and administrative expenses were approximately $5,700,000 for the quarter, which compares to $10,100,000 for the same period in the prior year. The SG and A expenses for the quarter include approximately $900,000 in non cash stock based compensation. The overall decline in SG and A expenses were primarily due to lower employee related expenses in the current period as well as non recurring legal and advisory related expenses in the prior period. Research and development expenses were $5,200,000 for the quarter, which compares to $7,000,000 for the same period in the prior year. R and D expenses for the quarter included approximately $400,000 in non cash stock based compensation. Speaker 300:02:45The overall decline in R and D expenses resulted primarily due to both lower employee related expenses as well as lower third party development expenses for our WAVE program. Our net loss for the quarter was approximately $14,200,000 resulting in a loss per share of 0.74 dollars Cash used for the quarter was approximately $9,000,000 excluding cash raise related to our January equity offering. Our cash used for the quarter includes over $1,000,000 in prepaid annual expenses. As discussed on previous calls, we are focused on driving significant reductions in operating expenses and cash burn in the coming quarters. Now back to Jack to discuss our exciting innovation with Wave. Speaker 200:03:32Thanks, David. As discussed during our last earnings call, Accelerate is uniquely positioned to disrupt the microbiology susceptibility testing market, surpassing emerging positive blood culture and traditional isolated colony systems. The global antibiotic susceptibility testing market is estimated at close to $2,000,000,000 and growing at about 6% annually. Divided into 2 segments, the PBC market represents about $800,000,000 with the isolate market at approximately $1,000,000,000 WAVE offers a consolidated platform that can process both PVC and isolate specimens on the same instrument. Further key product differentiators include same shift results, scalability, high throughput workflow and profitable cost structures. Speaker 200:04:27We received positive feedback and strong interest in WAVE during the European Society of Clinical Microbiology and Infectious Disease Conference earlier this month. Our team presented several technical posters on WAVE. Accelerate was also chosen to participate in a session on breakthrough innovation in microbiology. 1 of our leading scientists presented an oral presentation focused on the unique benefits of holographic imaging technology deployed on the WAVE system. Enthusiasm continues to grow from current and prospective customers. Speaker 200:05:06Moving to our preclinical trial, we have incurred an installation delay at our 2nd preclinical site due to final site contracting, and as a result, the preclinical study is still ongoing. However, we continue to target starting our clinical trial towards the end of the second quarter. No IVD clinical trial and FDA submission is without risk, but we feel confident in our team and ability to manage technical and timeline risks. In parallel to the clinical trial work, we are developing our gram positive PBC menu. Once completed, this will round out our PBC menu before moving on to the high volume isolate testing segment. Speaker 200:05:54Now turning to our WAVE commercial strategy. The first step in our 3 step commercialization strategy is to extend our leadership in the rapid PBC AST market. To this end, we continue to present WAVE to our current base of loyal customers and secure long term rapid susceptibility testing contracts. The interest in WAVE remains very high due to its differentiated and highly valued features. Microbiologists, pharmacists and clinicians alike understand same shift reporting enables critical therapeutic adjustments, which improve patient care and hospital economics. Speaker 200:06:36In addition to our ongoing discussions with our existing customer base in both the U. S. And EMEA, we continue to present WAVE its unique benefits to over 500 accounts in our sales funnel. We remain focused on launching Wave and converting our existing customers as this provides a commercial platform for not only quick wins, but it also reduces our overall cash burn with an increased margin contribution per customer. Additionally, we submitted our 510 to the FDA for our ARC system, which is the 1st automated PBC sample preparation method to enable rapid PBC ID on Bruker's MALDI Biotyper instruments. Speaker 200:07:22This will give customers another option for RapidID and will complement WAVE. The second step of our commercialization strategy is to expand our available market by launching an isolate menu on the same instrument already in the lab producing PBC susceptibility results. Wave will deliver rapid same shift isolate results with a competitive cost structure and one of the largest up to date drug menus available compared to legacy isolate platforms. The last step in our commercial strategy is to pursue both geographic and technology expansion. Along with a commercial partner, our goal will be to expand beyond the U. Speaker 200:08:09S. And EMEA to be a true global provider of Rapid ID AST solutions. We will also be expanding the AST menu with more esoteric microorganisms and partnering with pharmaceutical companies to further enable their drug discovery. Also, we envision numerous applications of holographic imaging outside of rapid susceptibility testing, which we plan to pursue. And finally, as discussed on our prior call in late March, an important part of our strategy is signing a global partnership to commercialize our innovation with Wave. Speaker 200:08:50We continue to have robust interest in multiple partners. We remain confident in our ability to secure a partnership by midyear. In summary, we continue to make progress on WAVE timelines and deliverables. We are excited about the next phase of clinical trials and the FDA submission later this year. Our experience in the market and strong customer base will position us for early success with Wave upon launch. Speaker 200:09:19At this time, I'm happy to take any questions from our covering analyst. Operator00:09:25We will now begin the question and answer session. And the first question will come from Dustin Skowrons with William Blair. Please go ahead, sir. Speaker 400:09:35Hey, guys. Thanks for taking our questions and appreciate all the color on Wave. Just wondering if there's any more details you can provide on the conversations you're having with potential customers and how these customers are viewing Wave versus other competing solutions out there? Speaker 200:09:54Yes. Hi, Dustin. Yes, I'll take that one for us. Yes, as I said in my comment prepared remarks, we continue to have a lot of dialogue with customers on Wave. We are just at ECCMID where we met with customers that was in Barcelona, Spain. Speaker 200:10:14And then on a regular daily and weekly basis, we review the Wave portfolio with our customers and prospective high volume testing like the isolate market testing and rapid PVC in one platform is a very big deal. Secondly, the fact that we're seeing results today in about 4 hours, which is really will be the gold standard. I mean, today, Pheno is about 8 hours and the systems that have been approved on the market on average are around that as well. And then finally, the ability for the high volume throughput system for us to be able to compete on a price point in the isolate market. We do believe we can restate the isolate market because of the speed to result of around 4 hours versus overnight today for many of the legacy platforms. Speaker 200:11:30But all in all, we will be very competitive there and also competitive in the PVC pricing area as well. That resonates strongly as well. And again, we're getting a lot of consistent positive feedback and we've continued to secure customers, the existing customers long term contracts And they're also starting to request upgrade clauses in their current contracts as Wave becomes available. Speaker 400:12:00Great. That actually goes to my next question. Good to see that the percentage of customers went up to 70%. But when you actually get wave out with ARC, how would that transition look like from a typical Pheno customer to these new products? Speaker 200:12:19Yes. So, exactly, good question. So, we're working on that right now. One of the beauties of Wave is that we're going to give customers optionality relative to the RapidID solution. So for example, some customers already have a molecular prefer to use into the future, coupled with Wave for rapid susceptibility. Speaker 200:12:54Other customers have MALDI platforms and many, many microbiology labs today now are equipped with MALDI platforms because it is a growing segment. Those customers are very excited about the opportunity to produce MALDI in get a rapid ID off of MALDI in an hour or 2 versus today MALDI ID takes it's an overnight process. And so those customers will be transitioning to a complete solution with ARC plus Biotype or MALDI plus the wave susceptibility system. And again, that's so we're really covering all the bases there and having these dialogues and they've been again very positive to date. Speaker 400:13:58That's great to hear. Around ARC, just wondering if we can get an update on how the Bruker collaboration has been going and how this is bringing greater awareness to Accelerate's entire portfolio of products, including Wave? Speaker 200:14:15Yes. So, sure. So, our collaboration with Bruker is extremely positive, and we have a partnership with them to the partnership is basically to develop ARC with their Biotyper platforms that they have. We've successfully done that and we've already received comments back from the FDA and we've responded to those. And so bottom line is, is the ARC is under review today. Speaker 200:14:51And we expect to hear back from the FDA in the coming weeks and then be able to further determine when we believe we'll be successful in getting ARC on the market in the U. S. Speaker 400:15:09Understood. And then just one last one for us. The collaboration you have with BD, just wondering if you can talk about any stage progression, funnel velocity and what this is doing to enhance placements with Pheno or for future products? Thank you. Speaker 200:15:33Yes, absolutely. I'm going to let David Patience take that one for us. Speaker 300:15:37Thanks, Dustin. Appreciate the question. So in the quarter, we contracted 12 new Pheno instruments and brought another 8 instruments blood culture, which is an important competitive mode for us with emerging competitors. We see progress with the BD partnership and them getting comfortable selling rapid susceptibility, while we're also fortifying our existing loyal customer base as we discussed earlier. Both are key in our launch of Wave. Speaker 300:16:14As Jack mentioned, we are looking to further improve our economics for customer with Wave. And so securing new customers with BD while also preparing our existing customer base for a Wave transition both strategically important to us. Speaker 400:16:33Okay, great. Thank you, David. That's it from us. Thanks, Dustin. Operator00:16:39This concludes our question and answer session. I would like to turn the conference back over to Mr. Jack Phillips for any closing remarks. Please go ahead. Speaker 200:16:47Sure. Thank you. In summary, we've made very good progress in several areas in the quarter. I'm really proud of our team and what we've accomplished. As highlighting some of those, as David mentioned, we added 12 new rapid AST systems in the quarter in conjunction with our partner BD. Speaker 200:17:08We executed percent of Accelerate's customer base to longer term contracts for WAVE. We successfully submitted a 510 through the FDA for ARC and we as I mentioned prior, we received confirmation already and our submission is currently under review. And then the WAVE program, we continue to make great progress. The preclinical trial remains underway. We're targeting still to begin clinical trials in late quarter 2. Speaker 200:17:46And we've also began development of gram positive, the gram positive PBC menu. So a lot of good things happening there on the wavefront. And then finally, as David highlighted, we continue to implement initiatives to improve our cash burn and extend our runway. So that's going very well as well. I want to say thank you very much for tuning into our Q1 earnings call. Speaker 200:18:12We appreciate your interest in Accelerate and I wish you a great day. Operator00:18:17The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallAccelerate Diagnostics Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Accelerate Diagnostics Earnings HeadlinesAccelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.comApril 26 at 2:11 AM | americanbankingnews.comAccelerate Diagnostics CEO Retention Bonus AgreementApril 25 at 6:13 PM | tipranks.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 26, 2025 | Paradigm Press (Ad)Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.comApril 20, 2025 | americanbankingnews.comAccelerate Diagnostics board forms committee to exlore strategic alternativesApril 16, 2025 | markets.businessinsider.comAccelerate Diagnostics to Explore Strategic AlternativesApril 15, 2025 | marketwatch.comSee More Accelerate Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Accelerate Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accelerate Diagnostics and other key companies, straight to your email. Email Address About Accelerate DiagnosticsAccelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.View Accelerate Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 5 speakers on the call. Operator00:00:00day, and welcome to the Accelerate Diagnostics Incorporated Quarter 2024 Results Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions with our covering analysts. I would now like to turn the conference over to Ms. Laura Pearson of Accelerant Diagnostics. Operator00:00:17Please go ahead, ma'am. Speaker 100:00:21Before we begin, it is important to share that information presented during this call may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward looking statements include projections, statements about our future and those that are not historical facts. All forward looking statements are made during this conference call are subject to risks, uncertainties and other factors that could cause our results to differ materially. These are discussed in greater detail in our annual report on Form 10 ks for the year ended December 31, 2023, and other reports we file with the SEC. It is my pleasure to now introduce the company's President and CEO, Jack Phillips. Speaker 200:01:10Thank you, Laura. Good afternoon. Today, I would like to provide a detailed update on the WAVE program. Before I provide my update, I will pass it on to David Patience, our CFO, to summarize our financial results for the quarter. Speaker 300:01:25Thank you, Jack, and good afternoon, everyone. Net sales were approximately to approximately $2,800,000 for the same period in the prior year. This was driven by an increase in reoccurring consumable net sales. Gross margin was approximately 25% for the quarter, which compares to approximately 36% for the same period in the prior year. The overall decline in gross margin was driven by product mix. Speaker 300:01:56Selling, general and administrative expenses were approximately $5,700,000 for the quarter, which compares to $10,100,000 for the same period in the prior year. The SG and A expenses for the quarter include approximately $900,000 in non cash stock based compensation. The overall decline in SG and A expenses were primarily due to lower employee related expenses in the current period as well as non recurring legal and advisory related expenses in the prior period. Research and development expenses were $5,200,000 for the quarter, which compares to $7,000,000 for the same period in the prior year. R and D expenses for the quarter included approximately $400,000 in non cash stock based compensation. Speaker 300:02:45The overall decline in R and D expenses resulted primarily due to both lower employee related expenses as well as lower third party development expenses for our WAVE program. Our net loss for the quarter was approximately $14,200,000 resulting in a loss per share of 0.74 dollars Cash used for the quarter was approximately $9,000,000 excluding cash raise related to our January equity offering. Our cash used for the quarter includes over $1,000,000 in prepaid annual expenses. As discussed on previous calls, we are focused on driving significant reductions in operating expenses and cash burn in the coming quarters. Now back to Jack to discuss our exciting innovation with Wave. Speaker 200:03:32Thanks, David. As discussed during our last earnings call, Accelerate is uniquely positioned to disrupt the microbiology susceptibility testing market, surpassing emerging positive blood culture and traditional isolated colony systems. The global antibiotic susceptibility testing market is estimated at close to $2,000,000,000 and growing at about 6% annually. Divided into 2 segments, the PBC market represents about $800,000,000 with the isolate market at approximately $1,000,000,000 WAVE offers a consolidated platform that can process both PVC and isolate specimens on the same instrument. Further key product differentiators include same shift results, scalability, high throughput workflow and profitable cost structures. Speaker 200:04:27We received positive feedback and strong interest in WAVE during the European Society of Clinical Microbiology and Infectious Disease Conference earlier this month. Our team presented several technical posters on WAVE. Accelerate was also chosen to participate in a session on breakthrough innovation in microbiology. 1 of our leading scientists presented an oral presentation focused on the unique benefits of holographic imaging technology deployed on the WAVE system. Enthusiasm continues to grow from current and prospective customers. Speaker 200:05:06Moving to our preclinical trial, we have incurred an installation delay at our 2nd preclinical site due to final site contracting, and as a result, the preclinical study is still ongoing. However, we continue to target starting our clinical trial towards the end of the second quarter. No IVD clinical trial and FDA submission is without risk, but we feel confident in our team and ability to manage technical and timeline risks. In parallel to the clinical trial work, we are developing our gram positive PBC menu. Once completed, this will round out our PBC menu before moving on to the high volume isolate testing segment. Speaker 200:05:54Now turning to our WAVE commercial strategy. The first step in our 3 step commercialization strategy is to extend our leadership in the rapid PBC AST market. To this end, we continue to present WAVE to our current base of loyal customers and secure long term rapid susceptibility testing contracts. The interest in WAVE remains very high due to its differentiated and highly valued features. Microbiologists, pharmacists and clinicians alike understand same shift reporting enables critical therapeutic adjustments, which improve patient care and hospital economics. Speaker 200:06:36In addition to our ongoing discussions with our existing customer base in both the U. S. And EMEA, we continue to present WAVE its unique benefits to over 500 accounts in our sales funnel. We remain focused on launching Wave and converting our existing customers as this provides a commercial platform for not only quick wins, but it also reduces our overall cash burn with an increased margin contribution per customer. Additionally, we submitted our 510 to the FDA for our ARC system, which is the 1st automated PBC sample preparation method to enable rapid PBC ID on Bruker's MALDI Biotyper instruments. Speaker 200:07:22This will give customers another option for RapidID and will complement WAVE. The second step of our commercialization strategy is to expand our available market by launching an isolate menu on the same instrument already in the lab producing PBC susceptibility results. Wave will deliver rapid same shift isolate results with a competitive cost structure and one of the largest up to date drug menus available compared to legacy isolate platforms. The last step in our commercial strategy is to pursue both geographic and technology expansion. Along with a commercial partner, our goal will be to expand beyond the U. Speaker 200:08:09S. And EMEA to be a true global provider of Rapid ID AST solutions. We will also be expanding the AST menu with more esoteric microorganisms and partnering with pharmaceutical companies to further enable their drug discovery. Also, we envision numerous applications of holographic imaging outside of rapid susceptibility testing, which we plan to pursue. And finally, as discussed on our prior call in late March, an important part of our strategy is signing a global partnership to commercialize our innovation with Wave. Speaker 200:08:50We continue to have robust interest in multiple partners. We remain confident in our ability to secure a partnership by midyear. In summary, we continue to make progress on WAVE timelines and deliverables. We are excited about the next phase of clinical trials and the FDA submission later this year. Our experience in the market and strong customer base will position us for early success with Wave upon launch. Speaker 200:09:19At this time, I'm happy to take any questions from our covering analyst. Operator00:09:25We will now begin the question and answer session. And the first question will come from Dustin Skowrons with William Blair. Please go ahead, sir. Speaker 400:09:35Hey, guys. Thanks for taking our questions and appreciate all the color on Wave. Just wondering if there's any more details you can provide on the conversations you're having with potential customers and how these customers are viewing Wave versus other competing solutions out there? Speaker 200:09:54Yes. Hi, Dustin. Yes, I'll take that one for us. Yes, as I said in my comment prepared remarks, we continue to have a lot of dialogue with customers on Wave. We are just at ECCMID where we met with customers that was in Barcelona, Spain. Speaker 200:10:14And then on a regular daily and weekly basis, we review the Wave portfolio with our customers and prospective high volume testing like the isolate market testing and rapid PVC in one platform is a very big deal. Secondly, the fact that we're seeing results today in about 4 hours, which is really will be the gold standard. I mean, today, Pheno is about 8 hours and the systems that have been approved on the market on average are around that as well. And then finally, the ability for the high volume throughput system for us to be able to compete on a price point in the isolate market. We do believe we can restate the isolate market because of the speed to result of around 4 hours versus overnight today for many of the legacy platforms. Speaker 200:11:30But all in all, we will be very competitive there and also competitive in the PVC pricing area as well. That resonates strongly as well. And again, we're getting a lot of consistent positive feedback and we've continued to secure customers, the existing customers long term contracts And they're also starting to request upgrade clauses in their current contracts as Wave becomes available. Speaker 400:12:00Great. That actually goes to my next question. Good to see that the percentage of customers went up to 70%. But when you actually get wave out with ARC, how would that transition look like from a typical Pheno customer to these new products? Speaker 200:12:19Yes. So, exactly, good question. So, we're working on that right now. One of the beauties of Wave is that we're going to give customers optionality relative to the RapidID solution. So for example, some customers already have a molecular prefer to use into the future, coupled with Wave for rapid susceptibility. Speaker 200:12:54Other customers have MALDI platforms and many, many microbiology labs today now are equipped with MALDI platforms because it is a growing segment. Those customers are very excited about the opportunity to produce MALDI in get a rapid ID off of MALDI in an hour or 2 versus today MALDI ID takes it's an overnight process. And so those customers will be transitioning to a complete solution with ARC plus Biotype or MALDI plus the wave susceptibility system. And again, that's so we're really covering all the bases there and having these dialogues and they've been again very positive to date. Speaker 400:13:58That's great to hear. Around ARC, just wondering if we can get an update on how the Bruker collaboration has been going and how this is bringing greater awareness to Accelerate's entire portfolio of products, including Wave? Speaker 200:14:15Yes. So, sure. So, our collaboration with Bruker is extremely positive, and we have a partnership with them to the partnership is basically to develop ARC with their Biotyper platforms that they have. We've successfully done that and we've already received comments back from the FDA and we've responded to those. And so bottom line is, is the ARC is under review today. Speaker 200:14:51And we expect to hear back from the FDA in the coming weeks and then be able to further determine when we believe we'll be successful in getting ARC on the market in the U. S. Speaker 400:15:09Understood. And then just one last one for us. The collaboration you have with BD, just wondering if you can talk about any stage progression, funnel velocity and what this is doing to enhance placements with Pheno or for future products? Thank you. Speaker 200:15:33Yes, absolutely. I'm going to let David Patience take that one for us. Speaker 300:15:37Thanks, Dustin. Appreciate the question. So in the quarter, we contracted 12 new Pheno instruments and brought another 8 instruments blood culture, which is an important competitive mode for us with emerging competitors. We see progress with the BD partnership and them getting comfortable selling rapid susceptibility, while we're also fortifying our existing loyal customer base as we discussed earlier. Both are key in our launch of Wave. Speaker 300:16:14As Jack mentioned, we are looking to further improve our economics for customer with Wave. And so securing new customers with BD while also preparing our existing customer base for a Wave transition both strategically important to us. Speaker 400:16:33Okay, great. Thank you, David. That's it from us. Thanks, Dustin. Operator00:16:39This concludes our question and answer session. I would like to turn the conference back over to Mr. Jack Phillips for any closing remarks. Please go ahead. Speaker 200:16:47Sure. Thank you. In summary, we've made very good progress in several areas in the quarter. I'm really proud of our team and what we've accomplished. As highlighting some of those, as David mentioned, we added 12 new rapid AST systems in the quarter in conjunction with our partner BD. Speaker 200:17:08We executed percent of Accelerate's customer base to longer term contracts for WAVE. We successfully submitted a 510 through the FDA for ARC and we as I mentioned prior, we received confirmation already and our submission is currently under review. And then the WAVE program, we continue to make great progress. The preclinical trial remains underway. We're targeting still to begin clinical trials in late quarter 2. Speaker 200:17:46And we've also began development of gram positive, the gram positive PBC menu. So a lot of good things happening there on the wavefront. And then finally, as David highlighted, we continue to implement initiatives to improve our cash burn and extend our runway. So that's going very well as well. I want to say thank you very much for tuning into our Q1 earnings call. Speaker 200:18:12We appreciate your interest in Accelerate and I wish you a great day. Operator00:18:17The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by